check_circleStudy Completed

Biological Availability

Drug-drug interaction (DDI) study to assess ODM-201 as a victim of CYP3A4 inhibition or induction

Trial purpose

Evaluate the effect of a probe CYP3A4 inhibitor and inducer on the pharmacokinetics of BAY1841788 (ODM-201)

Key Participants Requirements

Sex

Male

Age

45 - 65 Years

Trial summary

Enrollment Goal
15
Trial Dates
February 2017 - July 2017
Phase
Phase 1
Could I Receive a placebo
No
Products
Nubeqa (Darolutamide, BAY1841788)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
CRS Clinical Research Services Berlin GmbHBerlin, 13353, Germany

Primary Outcome

  • Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of Darolutamide in Plasma After Single Dose Administration of Darolutamide
    Area under the concentration versus time curve from time zero to 72 hours of Darolutamide after single dose administration in plasma were measured.
    date_rangeTime Frame:
    Pre dose to 72 hours post dose of darolutamide
    enhanced_encryption
    Safety Issue:
    No
  • Maximum Observed Concentration (Cmax) of Darolutamide in Plasma After Single Dose Administration of Darolutamide
    Maximum observed concentration after single dose administration in plasma were measured.
    date_rangeTime Frame:
    Pre dose up to 72 hours post dose of darolutamide
    enhanced_encryption
    Safety Issue:
    No
  • Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of (S,R)-Darolutamide in Plasma After Single Dose Administration of Darolutamide
    Area under the concentration versus time curve from time zero to 72 hours of (S,R)-Darolutamide in plasma after single dose administration of Darolutamide were measured.
    date_rangeTime Frame:
    Pre dose up to 72 hours post dose of darolutamide
    enhanced_encryption
    Safety Issue:
    No
  • Maximum Observed Concentration (Cmax) of (S,R)-Darolutamide in Plasma After Single Dose Administration of Darolutamide
    Maximum observed concentration of (S,R)-darolutamide in plasma after single dose administration of darolutamide were measured.
    date_rangeTime Frame:
    Pre dose up to 72 hours post dose of darolutamide
    enhanced_encryption
    Safety Issue:
    No
  • Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of (S,S)-Darolutamide in Plasma After Single Dose Administration of Darolutamide
    Area under the concentration versus time curve from time zero to 72 hours of (S,S)-darolutamide in plasma after single dose administration of darolutamide were measured.
    date_rangeTime Frame:
    Pre dose up to 72 hours post dose of darolutamide
    enhanced_encryption
    Safety Issue:
    No
  • Maximum Observed Concentration (Cmax) of (S,S)-Darolutamide in Plasma After Single Dose Administration of Darolutamide
    Maximum observed concentration of (S,S)-darolutamide in plasma after single dose administration of darolutamide were measured.
    date_rangeTime Frame:
    Pre dose up to 72 hours post dose of darolutamide
    enhanced_encryption
    Safety Issue:
    No
  • Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of Keto-Darolutamide in Plasma After Single Dose Administration of Darolutamide
    Area under the concentration versus time curve from time zero to 72 hours (AUC[0-72h]) of keto-Darolutamide in plasma after single dose administration of darolutamide were measured.
    date_rangeTime Frame:
    Pre dose up to 72 hours post dose of darolutamide
    enhanced_encryption
    Safety Issue:
    No
  • Maximum Observed Concentration (Cmax) of Keto-Darolutamide in Plasma After Single Dose Administration of Darolutamide
    Maximum observed concentration of keto-darolutamide in plasma after single dose administration of darolutamide were measured.
    date_rangeTime Frame:
    Pre dose up to 72 hours post dose of darolutamide
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Number of Subjects With Study Drug-Related Treatment Emergent Adverse Events (TEAEs)
    An adverse event (AE) was any untoward medical occurrence in subject who received study drug without regard to possibility of causal relationship. AEs that started or worsened after first administration of study medication up to 30 days after end of treatment with study medication were considered to be treatment-emergent (TE). AEs that occurred on study drug administration were termed as study drug related adverse events.
    date_rangeTime Frame:
    From start of study drug administration up to 30 days after last dose of study medication
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

A Phase I, non-randomized, open-label, fixed-sequence study to investigate the effect of a probe CYP3A4 inhibitor and inducer on the pharmacokinetics of BAY1841788 (ODM 201) in healthy male volunteers
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Other
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1